COO (The Cooper Companies) Stock Forecast 2026

Why COO Is Worth Watching in 2026 — And What Most Summaries Miss

Most stock write-ups on The Cooper Companies start with a revenue table and stop there. That misses the point. COO is fundamentally a business built on two slow-but-persistent tailwinds: the global myopia epidemic and the secular rise in demand for assisted reproduction. Neither of those trends reverses in a single year. What changes year to year is execution, mix, and whether the premium pricing power holds.

This analysis takes a qualitative, structural view. I won’t manufacture price targets or EPS forecasts — those change every quarter and you should pull them directly from SEC EDGAR or Cooper’s investor relations page. What I’ll do instead is map out what actually drives this business, where the risks are concentrated, and what scenarios would make the bull or bear case materially stronger.

---

What Kind of Company Is The Cooper Companies, Really?

It’s tempting to lump COO in with broad medical device names like Medtronic (MDT) or Stryker (SYK), but the business model is quite different. COO is primarily a consumables company.

A contact-lens wearer buys new lenses every day, every two weeks, or every month — for the rest of their life. That creates subscription-like recurring revenue without requiring a subscription model. CooperVision doesn’t need its customers to upgrade their “hardware” because the product is the consumable.

CooperSurgical leans more toward capital equipment in some segments (IVF lab instruments) but also has a consumables layer (fertility media, PARAGARD IUDs, other gynecological devices). The combination gives COO a revenue stream that’s stickier than pure device companies that depend on procedure volume and hospital capex cycles.

This is the foundational bull argument for the stock — not a hot product cycle, but a structural consumption model in growing end markets.

---

CooperVision: The Lens Portfolio That Matters

CooperVision is the larger of the two segments and the one most analysts focus on. Here’s how to think about the product ladder:

Lens Category	Key Characteristic	COO Position
Daily silicone-hydrogel	Premium comfort, fastest-growing format	Competitive, broad SKU range
Toric (astigmatism)	Specialty fit, higher ASP	Strong — toric specialty is a CooperVision emphasis
Multifocal (presbyopia)	Aging-population driven, premium-priced	Competitive niche, growing with demographics
MiSight (myopia management)	FDA-cleared, pediatric, first-mover	Sole first-mover advantage in approved category

The single most strategically important product is MiSight. It’s not just another lens — it’s a lens that gets prescribed to children, which means:

1. A new patient cohort that didn’t previously wear contact lenses
2. Parental willingness to pay premium pricing for a clinical benefit (slowing eye deterioration)
3. Prescribing habits established by optometrists who then become loyal CooperVision practitioners

Competitors are working on alternatives, but getting an FDA clearance for a myopia-management claim takes time. That regulatory moat is real, though not permanent.

---

The Myopia Epidemic Is Not Hype — Here’s What It Means for COO

The epidemiology is well-documented. Myopia rates among school-age children have risen sharply in East Asia for decades and are now climbing in Western countries too. The leading theories involve reduced outdoor time and prolonged near-work exposure from screens. No one is reversing that behavioral trend.

For COO, this has two separate effects:

Near-term: More myopic children and adults means more contact-lens wearers, period. Any increase in global myopia prevalence is a tailwind for all contact-lens makers, including competitors.

Long-term, COO-specific: MiSight targets the intervention market — parents who want to slow their child’s myopia progression, not just correct it. That’s a different value proposition with a clinical evidence base behind it. If optometrists become more proactive about prescribing myopia management (which clinical guidelines increasingly encourage), MiSight is positioned to capture disproportionate share.

The risk here is that Alcon, J&J Vision, or another player achieves a comparable clearance and competes directly on this claim. That’s a real scenario, not a remote one — watch FDA activity in the orthokeratology and soft-lens myopia-management space.

---

CooperSurgical: The Fertility Angle That Changes the Risk Profile

CooperSurgical doesn’t get as much attention as CooperVision, but it’s not a minor footnote. The segment covers:

• IVF and fertility consumables — culture media, biopsy tools, cryopreservation, embryo transfer catheters
• Contraception — PARAGARD (copper IUD), the largest non-hormonal IUD in the U.S.
• Gynecological devices — instruments used in office-based and surgical procedures

IVF volumes have been structurally increasing for years, driven by delayed childbearing, rising infertility rates, and expanding insurance coverage in some states and countries. CooperSurgical’s position as a consumables supplier to IVF clinics gives it exposure to that trend without requiring it to run the clinics itself.

PARAGARD is a different story — it’s a mature product with a specific niche (non-hormonal, long-acting contraception), and its market position is well-established but not high-growth. It generates steady cash flows.

The political and regulatory risk in this segment is real and has intensified. Anything that affects IVF access — legislative restrictions, reimbursement rollbacks, state-level policy changes — hits CooperSurgical directly. This is not a hypothetical risk for 2026; it’s an active monitoring item.

---

Who COO Is Really Competing Against

The competitive picture is different depending on which segment you’re analyzing.

CooperVision’s Competitive Set:

Competitor	Key Strength	Main Overlap with COO
Alcon (ALC)	Total Eye Care — lenses + surgical	Dailies, toric, multifocal; myopia management pipeline
J&J Vision (Acuvue)	Brand recognition, global distribution	Dailies franchise, premium positioning
Bausch + Lomb	Value and mid-market pricing	Broad lens portfolio, recent IPO/spinoff dynamics

CooperVision’s advantage is specialty depth — particularly toric and multifocal, where fitting complexity creates practitioner loyalty. Alcon has broader surgical ties that give it optometrist relationships, but CooperVision has historically been viewed as the specialty-lens specialist.

CooperSurgical’s Competitive Set:

The fertility space is more fragmented. Vitrolife, Origio (now part of CooperSurgical after the Origio acquisition), FUJIFILM Irvine Scientific, and Cook Medical all compete in IVF consumables. No single player dominates with the same market-share intensity as the contact-lens majors.

This is relevant context when comparing COO to other device companies. The competitive dynamics in fertility consumables are structurally different from the contact-lens oligopoly. For broader medical device context, see coverage of Abbott (ABT) and Boston Scientific (BSX).

---

What Makes the Bull Case Genuinely Compelling

This is not a “growth at any price” situation. The bull case for COO in 2026 rests on structural factors that don’t require macro luck:

1. The consumable moat compounds quietly. Every new contact-lens wearer who starts on a CooperVision product is a recurring revenue stream. Patient acquisition in ophthalmology is slow, but churn is even slower — people don’t switch lens brands often once they’ve been fitted.

2. Mix shift toward premium is already happening. Daily silicone-hydrogel lenses are displacing reusable lenses across the industry. Daily lenses cost more per year for the consumer but generate higher revenue per patient for the manufacturer. CooperVision has a full portfolio of daily SiHy options.

3. Myopia management is additive, not cannibalistic. MiSight creates a new patient segment — children who weren’t wearing contacts before — rather than replacing existing adult lens wearers.

4. IVF demand has a demographic tailwind. Delayed family formation and rising infertility awareness are secular trends in developed markets. CooperSurgical’s position in IVF consumables benefits from volume growth at its clinic customers without capital exposure.

5. Recurring revenue gives predictability. In uncertain macro environments, the market tends to value predictable cash flows. CooperVision’s model is as close to a subscription as you get in medical devices.

---

The Bear Case Isn’t Just FX — It’s More Fundamental

Bears on COO usually lead with currency headwinds, but that’s the least interesting risk. FX is cyclical; the structural risks are more worth examining.

Premium lens trade-down risk: If consumers feel economically pressured, some will shift from daily silicone-hydrogel lenses back to reusable lenses, or from contacts back to glasses. This is real — contact lenses are a discretionary spending decision for many wearers, even though they feel like a necessity.

MiSight competitive moat erosion: The FDA clearance for a myopia-management claim took years, but that clock is ticking for competitors too. If Alcon or J&J Vision receives a comparable clearance, MiSight loses its first-mover pricing power in what was previously a protected niche.

Fertility policy risk: Post-2022, reproductive health legislation has become unpredictable at the state level in the U.S. IVF has so far been largely shielded from restriction, but any material change in IVF accessibility or reimbursement would directly affect CooperSurgical’s volume.

Leverage from acquisitions: Cooper has made meaningful acquisitions (Generate Life Sciences being the most notable in recent years). Integrating those while maintaining margins is not trivial. If integration stumbles or goodwill impairment occurs, it affects reported results disproportionately.

Risk Category	Severity	Probability in 2026	What to Watch
FX headwinds (EUR, JPY, GBP)	Moderate	Elevated	USD strength trajectory
Premium lens trade-down	Moderate	Low-moderate	Consumer sentiment, economic data
MiSight competitive threat	High if realized	Low in 2026	FDA pipeline announcements
Fertility policy disruption	High if realized	Low-moderate	State/federal legislation
Integration execution risk	Moderate	Ongoing	Segment-level margin trends

---

Three Scenarios for COO in 2026

Rather than inventing price targets, here’s a qualitative sketch of how the thesis plays out across different environments.

Bull Scenario: Specialty Mix Shift Accelerates

CooperVision gains market share in daily SiHy and toric segments as eye-care practitioners consolidate their lens fitting around a smaller set of preferred brands. MiSight continues to grow its installed base, particularly in Asia-Pacific markets where myopia rates are highest and where parental demand for myopia management is culturally strong. CooperSurgical benefits from IVF volume growth in Europe and Asia, where reimbursement environments are more stable than the U.S. FX headwinds are moderate. Operating leverage from scale drives margin improvement. In this scenario, COO justifies premium valuation multiples because revenue growth is durable and margins are improving.

Base Scenario: Steady Execution, No Surprises

CooperVision grows roughly in line with the contact-lens market, with specialty lenses slightly outperforming commodity segments. MiSight grows its base but not dramatically, as practitioner adoption expands slowly outside existing markets. CooperSurgical delivers stable IVF consumables growth with PARAGARD flat-to-modest. FX creates a meaningful reported-growth headwind but doesn’t hide underlying demand. Valuation stays roughly stable relative to medtech peers.

Bear Scenario: Multiple Headwinds Converge

A stronger dollar significantly reduces reported international revenue. Premium lens wearers trade down in a weaker consumer environment. A competitor announces positive data on a myopia-management lens. A state legislature or court ruling creates uncertainty around IVF access, causing clinic customers to defer orders. Integration costs from prior acquisitions pressure margins. In this scenario, COO’s premium valuation compresses toward sector average — which itself could represent meaningful downside from elevated starting multiples.

---

How to Think About Valuation Without Making Up Numbers

COO is not a cheap stock. It has historically traded at a significant premium to both the S&P 500 and broad medtech indices. The justification is the recurring-revenue model, specialty positioning, and dual-growth-driver structure.

What that means practically is that when growth slows — even temporarily — the multiple compression can be disproportionate. High-multiple stocks punish misses harder than value stocks do.

The right framework for evaluating COO’s valuation is not a static comparison to peers. It’s a question of: is the premium justified by the quality and durability of the growth drivers?

For current valuation data — P/E, EV/EBITDA, forward estimates, analyst consensus — use SEC EDGAR (edgar.sec.gov) or Cooper’s official investor relations page at coopercos.com/investors. Don’t anchor on any number in this article; figures change every earnings cycle.

For comparison, it’s useful to look at how other specialty medtech names with high-recurring-revenue models are valued. DexCom (DXCM) is another example of a premium-multiple medtech with a consumables-driven model, and the valuation conversation there follows similar logic.

---

The Aging Population Angle — Multifocal Lenses and Presbyopia

A segment of the market that doesn’t get nearly enough attention in COO write-ups is multifocal contact lenses for presbyopia. As the global population ages — particularly in developed markets where Cooper has its heaviest distribution — more adults enter the age range where near-vision begins to deteriorate.

Presbyopia (age-related loss of near focus) typically begins affecting people in their early-to-mid 40s. Historically, presbyopic patients gave up contact lenses and switched to reading glasses or bifocals. Multifocal contact lenses have improved dramatically and now retain a meaningful share of these patients in the contact-lens category.

For CooperVision, this has two implications. First, it extends the revenue-generating life of existing contact-lens patients who might otherwise churn to eyeglasses. Second, it’s a premium-priced category where specialty fitting skills matter — the same dynamic that creates practitioner loyalty in toric lenses. CooperVision’s Biofinity Multifocal and Clariti Multifocal are positioned in this space.

This tailwind doesn’t require a new market to be created. It’s a retention mechanism embedded in demographic reality.

---

How CooperSurgical Built Scale in Fertility — And What That Means

CooperSurgical’s current scale in fertility consumables is not an overnight achievement. The segment has grown through a series of acquisitions over roughly a decade — companies specializing in IVF culture media, genetic testing for preimplantation diagnosis, cryopreservation, and embryo transfer tools.

Why does the acquisition-driven build matter for the thesis?

Because IVF is a highly protocol-driven field. Lab directors at fertility clinics develop strong preferences for specific consumables — particular culture media brands, specific catheter designs — and they’re reluctant to switch mid-treatment because the stakes (patient outcomes) are high. That creates sticky customer relationships once a brand is established in a clinic’s protocol.

The risk, as noted earlier, is integration. Every acquisition brings cultural friction, system differences, and the question of whether the acquired company’s specialized workforce stays post-acquisition. Cooper has a mixed track record in integration; it’s worth reading the acquisition commentary in recent earnings transcripts before drawing conclusions.

For comparison context, Abbott (ABT) has navigated similar acquisition-driven growth in diagnostics, and the challenges there parallel what Cooper faces in fertility.

---

Daily Lens Adoption Rates Still Have Room to Run

One of the most durable structural tailwinds for CooperVision is that global contact-lens adoption — and specifically daily lens adoption — is still not saturated.

In many markets, the penetration of daily silicone-hydrogel lenses remains relatively low. Markets in Asia (excluding Japan and South Korea which have high lens penetration), Latin America, and parts of Eastern Europe are still in earlier stages of premium lens adoption. As disposable incomes rise and optometry infrastructure expands in these markets, the addressable base for daily premium lenses grows.

This is not a short-term catalyst — it’s a decade-long story. But it’s precisely the kind of compounding opportunity that makes CooperVision’s recurring revenue model interesting over long holding periods rather than just the next quarter.

The caveat: this growth requires distribution infrastructure and regulatory approval in each market. Cooper has the international distribution already in place, but local market execution quality varies. Management’s commentary on emerging market contact-lens trends is worth tracking on earnings calls.

---

What to Monitor Through 2026

If you’re tracking COO as a long position or watchlist candidate, here’s what actually matters:

Earnings calls: Listen specifically to CooperVision segment organic growth (strip out FX), MiSight unit growth and geographic expansion commentary, and CooperSurgical’s IVF consumables volume trend. Margin commentary by segment matters more than headline numbers.

FDA pipeline: Any myopia-management lens applications from Alcon, J&J Vision, or Essilor-Luxottica are long-term competitive threats. Track FDA 510(k) and PMA clearances in the soft contact lens category.

Fertility policy news: Monitor state-level IVF legislation and any federal-level changes to reproductive health coverage. CooperSurgical is downstream from whatever happens at the clinic level.

Currency rates: EUR/USD and USD/JPY are the most relevant pairs given CooperVision’s European and Asian revenue base. A strengthening dollar reduces reported revenue growth even if unit volumes are healthy.

Integration of prior acquisitions: Cooper has absorbed several companies in recent years. Watch for any restructuring charges or goodwill discussion on earnings calls — those are signals about integration friction.

Contact-lens category data: The contact-lens market releases periodic market share data. Tracking CooperVision’s global share trend — stable, gaining, or losing — is a useful secondary indicator beyond just organic revenue growth. GfK and similar market research firms publish category-level data that analysts reference on earnings calls.

---

COO vs. the Broader Medtech Peer Group

COO sits in an interesting place in the medtech universe — it’s not a surgical robot, not a diagnostic company, and not a cardiovascular device maker. Its specialty consumables focus makes it more comparable to contact-lens peers than to broad medtech platforms.

That said, when investors rotate into or out of healthcare, COO often moves with the sector even when the underlying business hasn’t changed. This creates potential entry or exit points for investors who understand that the sector beta is real even when business fundamentals are divergent.

For broader context on the medtech space, the lens comparison with Abbott (ABT) is useful — ABT’s diagnostics and medical devices mix is very different from COO’s consumables model, but both are affected by the same healthcare spending environment. Similarly, Boston Scientific (BSX) operates in adjacent parts of the medical device spectrum with different risk and growth profiles.

The key differentiator for COO remains the contact-lens consumable flywheel. Very few medical device companies have a true daily consumable at scale. That’s worth a premium — the question is always how large a premium.

---

Final Take: Where COO Sits Heading Into 2026

The Cooper Companies is a business with two genuine structural tailwinds — global myopia prevalence and fertility demand — monetized through a recurring-revenue consumables model. That’s a more durable foundation than many medtech companies can claim.

The risks are real but mostly known: FX cyclicality, premium positioning vulnerability in a consumer downturn, competitive pressure on MiSight, and political uncertainty around reproductive health policy. None of these are existential, but they can combine to create significant near-term volatility.

What I’d tell an investor looking at COO for the first time: understand that you’re paying a premium for revenue quality, not for revenue growth speed. The market already knows about MiSight. The market already knows about IVF. What you’re betting on is whether execution over the next several years justifies the premium being paid today.

Check the current numbers at Cooper’s IR page and SEC EDGAR. Form your own view on the valuation. But on the quality of the underlying business — the recurring model, the specialty positioning, the dual-growth-driver structure — the bull case has a coherent foundation that doesn’t require heroic assumptions.

---

This article is for informational purposes only and does not constitute investment advice. All financial data including revenue, EPS, margins, and price targets should be verified directly through SEC EDGAR (edgar.sec.gov) or The Cooper Companies’ official investor relations page. Past stock performance does not predict future results.